talniflumate has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agostini, A; Alfieri, S; Arena, S; Bizzozero, L; Bria, E; Caggiano, A; Carbone, C; Corbo, V; De Sanctis, F; Esposito, A; Guerriero, I; Larghi, A; Lucchetti, D; Musella, M; Piro, G; Priori, L; Quero, G; Rizzatti, G; Roberto, L; Scaglione, G; Sgambato, A; Sistigu, A; Tortora, G; Ugel, S | 1 |
1 other study(ies) available for talniflumate and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Mice; Mucins; Pancreatic Intraductal Neoplasms; Pancreatic Neoplasms | 2023 |